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The PI3K-mTOR pathway is involved in regulating all hallmarks of cancer, and is often dysregulated in 
NSCLC, making it an attractive therapeutic target in this setting. Acquired resistance to PI3K-mTOR 
inhibition is a major hurdle to overcome in the success of PI3K-mTOR targeted agents. H460, A549, and 
H1975 resistant cells were generated by prolonged treatment in culture with Apitolisib (GDC-0980), a 
dual PI3K-mTOR inhibitor over a period of several months, from age-matched parent cells. Resistance 
was deemed to have developed when a log fold difference in IC50 had been achieved. Resistant cell 
lines also exhibited resistance to another widely investigated PI3K-mTOR dual inhibitor; Dactolisib 
(BEZ235). Cell lines were characterised at the level of mRNA (expression array profiling expression 
of >150 genes), miRNA (expression array profiling of 2100 miRNAs), protein (bottoms-up label-free 
mass spectrometry) and phosphoprotein (expression array profiling of 84 phospho/total proteins). 
Key alterations were validated by qPCR and Western blot. H1975 cells were initially most sensitive to 
Apitolisib (GDC-0980), but developed resistance more quickly than the other cell lines, perhaps due to 
increased selective pressure from the impressive initial effect. In-depth molecular profiling suggested 
epithelial-mesenchymal transition (EMT) may play a role in resistance to PI3K-mTOR dual inhibition in 
NSCLC.
Despite advances in anti-cancer therapies, the overall 5 year survival for lung cancer remains poor, at less than 
15%. As such it is crucial that we determine new strategies to overcome this formidable disease. Non-small cell 
lung cancer (NSCLC) refers to all histological subtypes of lung cancer other than small cell lung cancer, and 
accounts for ~80% of lung cancers.
Phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) signalling can induce all eight hallmarks of cancer in 
NSCLC and other cancers, and as such a plethora of PI3K targeted inhibitors have been developed in recent years 
with a view to halting oncogenic signalling in cancer cells1–5. Results of early phase clinical trials with single-agent 
PI3K inhibitors have shown only modest activity in NSCLC with innate and acquired resistance to PI3K path-
way inhibition a major hurdle to overcome in the development of these drugs. It is hoped that the mechanisms 
underlying the development of acquired resistance will highlight potential targetable weaknesses in the resistant 
tumour phenotype, allowing for the design of a combination approach which reinstates a blockade on survival 
signalling and allows for a more durable response to treatment.
Acquired resistance to PI3K inhibition has not been well characterised in NSCLC, although mechanisms are 
beginning to be elucidated in other cancer types. A mouse model engineered to conditionally express PIK3CA 
(H1047R) has revealed that focal amplification of either MET or c-MYC was present in tumours which reoc-
curred after PIK3CA inactivation. The MET amplified tumours could be inhibited with a selective PI3K inhibitor, 
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but the c-MYC-amplified tumours became independent of the PI3K pathway and refractory to treatment with 
a PI3K inhibitor6. c-MYC was also independently identified as a candidate PI3K resistance mechanism to dual 
PI3K-mTOR inhibitor Dactolisib (BEZ235), along with eIF4E7. A chemical-genetic screen also revealed c-MYC 
and Notch1 to be involved in resistance to PI3K inhibition8. Overexpression of IGF1R was also found to be pres-
ent in four cell line models of acquired resistance to PI3K inhibition, and IGF1R inhibition was shown to reverse 
this resistance9. AKT3 has also recently been implicated in resistance to the AKT inhibitor, MK2206 in breast 
cancer10.
A growing body of evidence has implicated activation of the epithelial to mesenchymal transition (EMT) pro-
gram in resistance to targeted therapy11,12. EMT is characterized by the upregulation of vimentin expression and 
inhibition of e-cadherin expression, denoting tissue reprogramming and often associated with a cancer stem cell 
phenotype. miRNAs are increasingly being implicated in resistance to anti-cancer treatments, including targeting 
therapies, often through regulation of EMT13–17. Furthermore, miRNAs have been shown to be involved in the 
dysregulation of the PI3K pathway during response/resistance to other treatments, leading us to hypothesize that 
miRNA may play a role in mediating resistance to PI3K inhibitors, possibly through EMT18–20. MiR-205 has been 
linked to advanced cancers and is a master regulator of EMT. The most prominent gene targets of miR-205 are the 
e-cadherin transcriptional repressors Zeb1 and Zeb2. Zeb1, Zeb2 and other transcription factors exert their effect 
by binding to 2 bi-partite E box motifs within the e- cadherin promoter, thereby repressing transcription11,21–24.
In this study, three NSCLC cell lines (with different driver mutation profiles) were exposed to the dual 
PI3K-mTOR inhibitor Apitolisib (GDC-0980) over an extended period with the aim of inducing acquired resist-
ance. Apitolisib was being investigated clinically in NSCLC at the time of the development of these cell lines, 
though dactolisib (BEZ235) has since become more heavily investigated in the clinical setting25. Our apitolisib 
resistant cell lines have been shown to also exhibit resistance to dactolisib (BEZ235), making these an ideal model 
for elucidating mechanisms of PI3K-mTOR inhibition. Mechanisms of resistance were characterised at the level 
of DNA, mRNA, miRNA, protein and protein phosphorylation.
Materials and Methods
Cell lines and drugs. H460, A549 and H1975 cell lines were purchased from the European Culture and 
Tissue Collection. Apitolisib (GDC-0980) was gifted under a material transfer agreement from Genentech for 
use in this study, and was dissolved in dimethyl sulphoxide (DMSO), aliquoted and stored at −20 °C. Dactolisib 
(BEZ235) was purchased from Selleckchem, dissolved in DMSO, aliquoted and stored at −20 °C.
Cell culture. H460 and H1975 cells were grown in RPMI1640 media (Lonza) supplemented with 10% FBS 
and 1% penicillin/streptomycin at 37 °C and 5% CO2. A549 cells were grown in Ham’s F-12 media (Lonza) sup-
plemented with 10% FBS, 1% penicillin/streptomycin and 1% L-glutamine at 37 °C and 5% CO2. Three Apitolisib 
(GDC-0980) resistant cell lines were developed during the course of this study. Lung cancer cell lines H460, 
A549 and H1975 were treated with IC50 concentrations of Apitolisib (GDC-0980), as calculated from a BrdU 
proliferation assay for a period of 4–12 months. H460GR (H460 GDC-0980 resistant) cells were maintained 
in 1.69 µM GDC-0980, A549GR (A549 GDC-0980 resistant) cells were maintained in 3.44 µM GDC-0980 and 
H1975GR (H1975 GDC-0980 resistant) cells were maintained in 0.58 µM Apitolisib (GDC-0980) in addition to 
medium supplemented as described above. BrdU assays were carried out each month to assess the development 
of resistance to Apitolisib (GDC-0980) by comparing resistant cells (H460GR, A549GR and H1975GR) IC50 to 
age-matched parental cells (H460GP, A549GP and H1975GP) IC50. When matched parent-resistant cell line 
pairs reached a log fold difference in IC50, acquired resistance was deemed to have developed. All cell lines were 
tested for mycoplasma once per month by the polymerase chain reaction (PCR) method26. Cell line samples from 
before, during and after the period during which these experiments were carried out were authenticated by DNA 
Diagnostics Centre.
Proliferation assays. Cell proliferation was measured using a Cell Proliferation enzyme linked immuno-
sorbent assay (ELISA), BrdU (Roche Diagnostics Ltd) and Cell Titre Blue assay (Promega). Cells were seeded 
at 2000 cells per well in a 96-well plate and adhered overnight. Cells were treated with Apitolisib (GDC-0980) 
or Dactolisib for 72 hr at a range of concentrations as noted (Fig. 1, Supplementary Figure 1). Following treat-
ment, 10 µL of a 1:1000 dilution of BrdU labelling solution (final concentration-10 µM) was added to each well 
and plates incubated for 4 hours at 37 °C. Following incubation, the media was removed and the cells fixed and 
denatured with 200 µL of a fixative solution for 30 minutes at room temperature. 100 µL anti-BrdU-POD (mouse 
monoclonal antibody, peroxidase-conjugated) working solution was added to each well for 90 minutes at RT. Cells 
were washed three times with wash buffer and 100 µL of substrate solution was added for 5–10 minutes (or until 
colour change was sufficient for photometric detection). 25 µL 1 mM H2SO4 was added to each well to stop the 
reaction. Absorbance was measured on a Vesamax tunable microplate reader at 450 nm with a reference wave-
length set to 690 nm. Alternatively, following treatment, CellTitre-Blue reagent was added to test plate (20 µL per 
well), shaken for 10 s and incubated for 4hrs, then shaken for 10 s and fluorescence was recorded at 560/590 nm.
Gene expression arrays. RNA was isolated from parent and resistant cell lines using the RNeasy mini kit 
(Qiagen). Two RT2 Profiler PCR array panels were used (mTOR signaling and cancer drug resistance) to compare 
H1975GR with H1975GP and H460GR with H460GP. cDNA was added to RT2 qPCR Master Mix, which con-
tains SYBR Green and reference dye. The experimental cocktail of cDNA, Master Mix and H2O was added to the 
96 well array (25 μl per well). Real-time PCR thermal cycling was performed using the ABI 7500 thermal cycler. 
Changes in gene expression between parent and Apitolisib (GDC-0980) resistant cell lines were analyzed using 
SABiosciences online software which incorporates the ΔΔCT method.
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miRNA expression profiling. miRNA expression profiling was carried out through Exiqon services 
(Vedbaek, Denmark) in order to identify differentially expressed miRNAs between parent and drug resistant cell 
lines. RNA was isolated from cell line samples using the miRNeasy kit (Qiagen) and cleaned using the miRCURY 
RNA isolation kit (Exiqon) as follows. The purified RNA sample was stored at −80 °C and shipped to Exiqon for 
analysis, where samples were labelled using the miRCURY LNA microRNA Hi-Power Labelling Kit, Hy3/Hy5 
and hybridized on the miRCURY LNA microRNA Array (7th generation). Quantified signals were normalized, 
the background was corrected and supervised and unsupervised data analyses were performed using the Quantile 
algorithm.
miRNA validation by RT-PCR. RNA was diluted to 5 ng/μl using RNase-free water. cDNA was synthesised 
using the miRCURY LNA™ Universal RT microRNA PCR, Starter Kit (Exiqon), briefly 2 μl 5X reaction buffer, 
4.5 μl nuclease-free water, 1 μl enzyme mix, 0.5 μl synthetic UniSp6 RNA spike-in and 2 μl template RNA (5 ng/μl). 
cDNA was amplified using Exilent SYBR Green Master Mix and microRNA LNA™ PCR primer sets U6 snRNA 
(endogenous control), hsa-miR-205-5p, and UniSp6 (quality control) (Exiqon). Fold change in miRNA expres-
sion was calculated using the ∆∆Ct method.
Mass Spectrometry. Cell pellets were lysed in a buffer containing 8 M urea/50 mM NH4HCO3/0.1% 
ProteaseMax. The protein amount was estimated using an RC/DC protein assay from Bio-Rad27. BSA was used 
as a standard. After dithiothreitol reduction and iodoacetic acid-mediated alkylation, a double digestion was 
performed using Lys-C (for 4 hours at 37 °C) and Trypsin (overnight at 37 °C) on 5 µg of protein. Digested sam-
ples were desalted prior to analysis using C18 spin columns (Thermo Scientific, UK). 500 ng of digested protein 
was analysed from each digest using a Q-Exactive mass spectrometer coupled to a Dionex RSLCnano (Thermo 
Scientific, Waltham, MA, USA). Peptides were separated using a 2% to 40% gradient of acetonitrile (A: 0.1% FA, 
B: 80% acetonitrile, 0.1% FA) on a Biobasic C18 Picofrit column (ThermoFisher Scientific, Hemel Hempstead, 
UK) (100 mm length, 75 mm ID) over 65 min at a flow rate of 250 nl/min. Data was acquired with the mass 
spectrometer operating in automatic data dependent switching mode. A full MS scan at 140,000 resolution and a 
range of 300–1700 m/z was followed by an MS/MS scan, resolution 17,500 and a range of 200–2000 m/z, selecting 
the 15 most intense ions prior to MS/MS (Top15 method)28.
Label-free analysis. Progenesis label-free LC-MS software version 3.1 from Non-Linear Dynamics 
(Newcastle upon Tyne, UK) was used to process the raw data generated from LC-MS/MS analysis. Data align-
ment was based on the LC retention time of each sample, allowing for any drift in retention time given and 
Figure 1. Development of GDC-0980 resistant NSCLC cell lines. A panel of NSCLC cell lines was exposed to 
GDC-0980 over an extended period in order to develop a cell line model of acquired resistance to the drug. 
(a) Work flow describing the development of GDC-0980 resistant NSCLC cell lines. (b) Parent and putative 
resistant cell lines reached a log fold difference in IC50 at month 4 for H1975 and month 5 for H460. After 12 
months, A549 cells did not develop resistance to the drug. Final BrdU proliferation assay results are shown 
here, where proliferation was normalized on a percentage scale. Assays were performed in triplicate wells and 
repeated three individual times (n = 3). Data is shown as mean ± SEM. IC50s were calculated separately by 
linear regression and are noted here. */**/***p < 0.05/0.01/0.001 respectively.
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adjusted retention time for all runs in the analysis. A reference run was established with the sample run that 
yielded most features (i.e. peptide ions). The retention times of all of the other runs were aligned to this reference 
run and peak intensities were then normalized29.
Prior to exportation to Proteome Discoverer 1.4 (Thermo Scientific), the MS/MS data files were filtered using 
the following parameters; (1) peptide features with ANOVA ≤ 0.05 between experimental groups, (2) mass peaks 
with charge states from +1 to +5 and (3) greater than one isotope per peptide. The PepXML generic file, gener-
ated from all exported MS/MS spectra, was used for peptide identification using Proteome Discoverer 1.4 against 
Sequest HT (SEQUEST HT algorithm, licence Thermo Scientific, registered trademark University of Washington, 
USA) and searched against the UniProtKB-SwissProt database (taxonomy: Homo sapiens). The following search 
parameters were used for protein identification: (1) peptide mass tolerance set to 10 ppm, (2) MS/MS mass tol-
erance set to 0.02 Da, (3) up to two missed cleavages were allowed, (4) carbamidomethylation set as a fixed mod-
ification and (5) methionine oxidation set as a variable modification. For re-importation back into Progenesis 
LC–MS software for further analysis, only peptides with XCorr scores >1.9 (+1), >2.2 (+2) >3.75 (+3) and high 
peptide confidence were selected. A number of criteria were applied to ensure proper identification/evaluation 
of cellular proteins, including an ANOVA p-value between experimental groups of ≤0.05, fold change ≥2 and 
proteins with ≥2 peptides matched30.
Phospho-protein profiling. Human phospho kinase arrays (R&D systems) were used to profile expression 
of 43 kinase phosphorylation sites and 2 related total proteins across a panel of cell lines. Capture and control anti-
bodies are spotted in duplicate on nitrocellulose membranes. Cell lysates were incubated with these membranes 
in a multi well dish overnight and detected by chemiluminescence. Proteins were isolated and quantified as per 
manufacturer’s instructions. Array buffer 1 (block buffer, 1 mL) was added to each well of the dish provided, and 
array membranes were added to relevant wells and incubated at RT for 1 hour on a shaker. Protein samples were 
diluted to 500 mg/2 mL with array buffer one, and then added to relevant wells and incubated at 4 °C overnight 
on a shaker. Three 10 minute washes was performed using 1X wash buffer, then membranes were incubated in 
detection antibody for 2 hours at room temperature on a shaker. A further three washes were carried out prior to 
membrane incubation in Strepdavidin-HRP for 30 minutes on a shaker. Three further washes were carried out 
and then membranes were incubated in Chemi Reagent Mix for 1 minute and spots visualized on a Biospectrum 
Imaging System. Densitometry analysis was carried out using ImageJ.
PathScan arrays (Cell Signalling Technologies) were used here to profile expression of 28 RTKs and 11 sig-
nalling nodes, when phosphorylated at tyrosine or other residues as noted. Protein samples were prepared and 
quantified as per kit guidelines. 100 µL blocking buffer was added to each well and incubated at RT for 15 minutes 
on a shaker. Cell lysates are diluted to 1 mg/mL and 75 µL of this working solution is added per well and incubated 
for overnight at 4 °C on a shaker. Four 5 minute washes were carried out using 1X array wash buffer, and 75 µL 
detection antibody cocktail was added. The slide was incubated at RT for 1 hour on a shaker, then four further 
5 minute washes were carried out. 75 µL HRP-linked Strepdavidin was added to each well and incubated for 
30 minutes at RT on a shaker. Four further 5 minute washes were carried out prior to incubation in LumiGlo/
peroxide mix (chemiluminescent reagent) for the duration of slide imaging using a Biospectrum Imaging System. 
Densitometry analysis was carried out using Image J.
Semi-Quantitative analysis of EMT related genes (Zeb1, Zeb2, E-cadherin) in matched H1975P 
and H1975GR cell lines. Total RNA from H1975P and H1975GR cell lines was extracted using 1 ml TRI 
Reagent and miRCURY LNA isolation kit (Exiqon) (as per manufacturer’s protocol). First strand comple-
mentary DNA (cDNA) was synthesised using 1 µg of total RNA and Superscript III reverse transcriptase kit 
(Invitrogen). Zeb1, Zeb2 and E-cadherin were amplified using primer sets outlined as follows: Zeb1 Forward (5′ 
TTCAAACCCATAGTGGTTGCT 3′), Zeb1 Reverse (5′ TGGGAGACACCAAACCAACTG 3′), Zeb2 Forward 
(5′ CAAGAGGCGCAAACAAGC 3′), Zeb2 Reverse (5′ GGTTGGCAATACCGTCATCC 3′), E-cadherin 
Forward (5′ CAGCACGTACACAGCCCTAA 3′), E-cadherin Reverse (5′ GCTGGCTCAAGTCAAAGTCC 3′). 
All primers sets had annealing temperatures of 60 °C. Amplicons were separated by electrophoresis through a 1% 
agarose gel and visualized under UV light. Densitometry analysis was carried out using ImageJ.
Western blot. Total protein was extracted on ice from H1975P and H1975GR cell lines using RIPA lysis 
buffer to which sodium orthovandate (50 mM), phenylmethylsulfonyl fluoride (PMSF) (100 mM), protease inhib-
itor cocktail, beta-glycerophosphate (500 nM) and sodium fluoride (500 nM) were added. 30 µg of each protein 
was separated by electrophoresis through a 12% SDS PAGE gel and proteins were transferred onto methanol 
activated PVDF membrane. After blocking in 1X TBST buffer containing 5% (w/v) non-fat dry milk for 1 hour 
at room temperature with gentle agitation, the membrane was washed three times for 5 minutes each in 1X TBST 
and incubated overnight at 4 °C with gentle agitation in 0.1 µg/mL Vimentin primary antibody (R&D Systems) 
and blocking buffer (5% (v/v) bovine serum albumin (BSA) in 1X TBST). The membrane was washed three times 
for 5 minutes each in 1X TBST and incubated for 1 hour at room temperature with gentle agitation in 0.1 µg/mL 
rabbit anti-goat secondary antibody (Santa Cruz). After washing membrane in 1X TBST bound antibody com-
plexes were detected using the Supersignal West Pico Chemiluminescent Substrate Kit (Thermo Scientific) and 
exposure to imaging X-Ray film (MG-SR Plus, Konica Minolta). Densitometry was carried out by ImageJ.
Data availability. All array data will be made available to the public via online repositories.
Results
H460, A549 and H1975 cells were exposed to Apitolisib (GDC-0980) at IC50 concentrations for 4–12 months. 
Monthly BrdU proliferation assays were carried out in order to assess the development of acquired resistance to 
the drug. H1975 (PIK3CA and PIK3R1 mutated) cells, which had been the most sensitive cell line to Apitolisib 
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(GDC-0980), began to show decreased sensitivity to the drug as early as 1 month after commencement of 
GDC-0980 treatment. The difference in IC50 concentration between parent (H1975GP) and putative resistant 
(H1975GR) cells reached a log fold at month 4 of Apitolisib (GDC-0980) treatment, at which point the cells were 
deemed to have developed resistance to the drug (Fig. 1). H460 (PIK3CA mutated) cells began to show decreased 
sensitivity to Apitolisib (GDC-0980) after 2 months of treatment with the drug, and reached a log fold difference 
in IC50 value between parent (H460GP) and resistant (H460GR) cells at month 5 of treatment. At this point the 
cells were deemed to have developed resistance to the drug (Fig. 1). A549 (PIK3CA wild-type) cells had been the 
least sensitive to PI3K treatment, with the highest IC50 concentration of the three cell lines examined. This cell 
line did not develop resistance to the drug after 12 months of treatment (Fig. 1). H1975GR cells were noted to also 
exhibit resistance to Dactolisib (BEZ235), a commonly investigated PI3K-mTOR dual inhibitor (Supplementary 
Figure 1).
Having developed two cell line models of resistance to Apitolisib (GDC-0980) (H1975GR and H460GR), 
an in-depth characterisation of the mechanisms of resistance to the drug was carried out. Data presented at the 
American Association for Cancer Research Special Conference: Targeting the PI3K-mTOR Network in Cancer 
showed that none of the resistant cell lines exhibited altered mutational profiles compared with matched parent 
cells31. Apitolisib (GDC-0980) resistant cell lines were compared with age matched parental controls using mRNA 
expression pfrofile arrays (SABiosciences). Two array panels were used here: one which profiles expression of 84 
genes related to cancer drug resistance, and one which profiles expression of 84 genes related to mTOR pathway 
signalling. H1975GR cells were found to overexpress aryl hydrocarbon receptor nuclear translocator (ARNT) 
53.45 fold, and have a downregulation of estrogen receptor beta (ESR2) 53.76 fold (Fig. 2), relative to parental 
cells. H1975GR cells were also found to overexpress AKT3 (174.7 fold) and insulin receptor (INSR) (5.56 fold), In 
addition to overexpression of PIK3C3 (3.59 fold), PIK3CD (3.28 fold), MTOR (2.18 fold) and a downregulation of 
DEP domain-containing mTOR-interacting protein (DEPTOR) 4.73 fold (Fig. 3). H460GR cells were also found 
to overexpress ARNT (6.32 fold), ERBB2 (15.97 fold), ERBB3 (12.35 fold) and ERBB4 (18329.77 old), while EGFR 
(−314.11 fold) and MYC (−4.89 fold) were downregulated (Fig. 2). H460GR cells showed overexpression of 
AKT3 (9.26 fold) and a downregulation of INSR (2.44 fold), and PRKCB (129.40 fold) (Fig. 2).
Figure 2. mRNA profile of GDC-0980 resistant NSCLC cell lines. Gene expression was assessed using RT2 
profiler arrays from SABiosciences (left: mTOR panel, right: cancer drug resistance panel) in order to compare 
gene expression in H1975GP, H1975GR, H406GP and H460GR cell lines. A clustergram was constructed using 
SABiosciences online software.
www.nature.com/scientificreports/
6SCIeNTIfIC RePORtS |  (2018) 8:1652  | DOI:10.1038/s41598-018-19688-1
MicroRNA expression profiling was carried out in H460GP, H460GR, H1975GP and H1975GR samples, 
using 7th generation miRCURY LNA microRNA Arrays. The total number of miRNAs which were expressed 
above background was 489. The top 50 of these (by magnitude of difference) are included in a heat map in Fig. 3. 
The most highly upregulated miRNA in H460GR cells compared to their parental H460GP counterparts was 
hsa-miRPlus-G1246-3p, while the most downregulated was hsa-miR-375. Hsa-miR-130a-3p was the most upreg-
ulated miRNA in H1975GR cells compared with H1975GP cells, and the most downregulated was hsa-miR205-5p 
(Fig. 3). Validation of EMT regulator hsa-miR205-5p by qPCR confirmed its expression in H1975GP cells how-
ever it was undetectable in H1975GR cells.
Proteomic analysis of H460GP, H460GR, H1975GP and H1975GR cell lines was carried out using bottoms-up 
label-free mass spectrometry (n = 3). 592 proteins were >2 fold differentially regulated, with p < 0.05 between 
H460GP and H460GR cell lines (Fig. 4). KEGG analysis highlighted activation of several regulators of EMT 
including vimentin (13 fold), desmin (12 fold) and filamin (28 fold) in H1975GR cell lines. The dataset was ana-
lysed using Ingenuity Pathway Analysis software, which identified alterations in eif2, eif4 and mTOR signalling. 
1173 proteins were >2 fold differentially regulated, with p < 0.05 between H1975GP and H1975GR cell lines. 
Alterations in pathways identified between these two cell lines included ubiquitination, Rho and PI3K/AKT sig-
nalling (Fig. 5).
Proteomic analysis of H1975GP and H1975GR cells highlighted a large number of proteins that may be 
involved in resistance to Apitolisib (GDC-0980). This was further investigated by interrogating intracellular sig-
nalling pathway activation by phosphorylation. To achieve this, both H1975GR and H460GR cell lines were com-
pared with their age-matched parental control cell lines using phospho-kinase arrays. (Supplemental Figure 2). 
H1975GR cells exhibited increased expression of AKT1/2/3 (T308) (2.03 fold), and decreased expression of 
PRAS40 (T246) (33.85 fold), AKT1/2/3 (S473) (15.29 fold), among others. H460GR cell exhibited increased 
expression of EGFR (Y1086) (1.47 fold), AKT1/2/3 (S473) (3.3 fold), ERK1/2 (T202/Y204) (2.8 fold) and p38α 
(T180/Y182) (8.2 fold) and decreased expression of p53 (S392, S46 and S15) (1.66 fold, 4.64 fold and 2.54 fold 
respectively), among others.
Further analysis of H1975GR cells using Ingenuity Pathway Analysis identified a number of alterations in 
proteins involved in epithelial-mesenchymal transition (EMT).
Figure 3. Heat map and hierarchical clustering of H460GP, H460GR, H1975GP and H1975GR miRNA screen. 
miRNA have previously been shown to regulate resistance to targeted therapies. Here, H460GP, H460GR, 
H1975GP and H1975GR miRNA samples were screened for miRNA expression by Exiqon services using the 
miRCURY LNA microRNA array. The top 50 miRNAs (in terms of differential expression) are hierarchically 
clustered here.
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Figure 6 downregulation of E-cadherin and upregulation of ZEB1 and ZEB2 were confirmed at the mRNA 
level by PCR, while upregulation of Vimentin protein was confirmed by Western blot (Fig. 6).
Discussion
This study set out to develop NSCLC cell line models of resistance to Apitolisib (GDC-0980), a dual PI3K-mTOR 
inhibitor which is currently in Phase II clinical trials for lymphomas and solid tumours. H1975GR cells were 
noted to also exhibit resistance to Dactolisib (BEZ235), another commonly investigated PI3K-mTOR dual inhib-
itor in Phase II trials for cancer. The cell line models were characterised in detail with a view to identifying targ-
etable mediators of resistance to the drug.
H460, A549 and H1975 cells were exposed to IC50 concentrations of Apitolisib (GDC-0980) over an extended 
period of time in order to develop cell line models of acquired resistance to the drug. H1975 cells, which were the 
most sensitive cell line to Apitolisib (GDC-0980) treatment, were the first to develop resistance. In fact, this cell 
line began to exhibit decreased sensitivity to the drug after just one month, and developed a log fold difference in 
IC50 concentration between parent (H1975GP) and resistant (H1975GR) cell lines after just 4 months of treat-
ment with Apitolisib (GDC-0980). H1975 cells were shown to harbour mutations in both PIK3CA and PIK3R1, 
Figure 4. Proteomic analysis of H460GP and H460GR cell lines. Protein was isolated from H460GP and 
H460GR cell lines and analysed by bottoms-up label-free mass spectrometry, in order to identify differences in 
protein abundance (n = 3). 592 proteins were significantly (p < 0.05) differentially regulated (fold change >2) 
between parent and GDC-0980 resistant cells. Data was analysed using Ingenuity Pathway Analysis. (a) Top 
dysregulated pathways are shown. (b) Differential regulation is shown in the context of the PI3K pathway.
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and have previously been shown to express PI3K pathway signalling phosphoproteins more highly than the other 
cell lines used here32.
It is hypothesized that the initial sensitivity to PI3K inhibition here could imply a reliance on PI3K pathway 
signalling, with the cells being addicted to the pathway. As such, the drug mediated significant effects in the short 
term, but the increased selective pressure lead to the cells becoming rapidly resistant to the drug.
H460 cells, which were also sensitive to Apitolisib (GDC-0980), though not as sensitive as H1975 cells, were 
the second cell line to develop drug resistance. Here, an initial decrease in sensitivity to Apitolisib (GDC-0980) 
was observed after 2 months, and a log fold difference in IC50 achieved after 5 months of treatment. H460 cells 
were shown to harbour a mutation in PIK3CA but not PIK3R1, and to express PI3K signalling molecules at lower 
levels than H1975 cells. This cell line, unlike H1975 cells, also harbours a mutation in KRAS. As such it is hypoth-
esized that this cell line does utilise PI3K signalling, but is not addicted to the pathway. Previously it has been 
hypothesized that some tumours could be dependent on mutant PIK3CA as a driver oncogene, whereas in other 
cases, the PIK3CA mutation may modulate the effect of another oncogenic process33. We hypothesize that H1975 
Figure 5. Proteomic analysis of H1975GP and H1975GR cell lines. Protein was isolated from H1975GP and 
H1975GR cell lines and analysed by bottoms-up label-free mass spectrometry, in order to identify differences 
in protein abundance (n = 3). 1173 proteins were significantly (p < 0.05) differentially regulated (fold change 
>2) between parent and GDC-0980 resistant cells. Data was analysed using Ingenuity Pathway Analysis. (a) Top 
dysregulated pathways are shown. (b) Differential regulation is shown in the context of the PI3K pathway.
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cells represent an example of the former, and H460 cells represent an example of the latter, where mutant KRAS 
is the driver mutation. As such, while H460 cells were less sensitive to PI3K inhibition initially, the effects of the 
drug were sustained over a longer period due to the reduced selective pressure.
Based on these data, we would hypothesize that patients who exhibit PI3K pathway activation, but not onco-
gene addiction to mutant PIK3CA, will undergo a moderate response to PI3K-mTOR inhibition, which will be 
sustained over a longer period than patients whose tumours exhibit addiction to mutant PIK3CA.
A549 cells were previously shown to exhibit mutated KRAS but wild-type PIK3CA, and were least sensitive to 
Apitolisib (GDC-0980), initially having a higher IC50 concentration than the other three cell lines. This cell line 
does not appear to rely on PI3K signalling, and may exhibit low levels of innate resistance to Apitolisib (GDC-
0980), although there is no established cut-off to define whether cells exhibit true innate resistance, or merely 
reduced sensitivity to the compound. After 12 months of treatment with Apitolisib (GDC-0980), A549 cells had 
not developed further resistance to the drug. As such, patients who do not exhibit significant activation of the 
PI3K pathway may benefit, in part, from PI3K inhibition, in that it may induce minimal effects, but sustain these 
effects over a longer period.
Detailed molecular characterisation of H1975GR and H460GR cell lines was carried out relative to their 
matched parent cell lines, at the level of DNA, mRNA, total and phospho-proteins. Several key trends were 
observed. AKT3 gene expression was greatly increased in all three Apitolisib (GDC-0980) resistant cell lines 
compared to their matched parent cell lines. AKT3 is the least studied isoform of AKT, with its precise role in cell 
signalling being poorly understood. Nonetheless, the gene has been associated with multiple disease phenotypes, 
Figure 6. Dysregulation of EMT in GDC-0980 resistant cells. (a)H1975PT and H1975GR cells were analysed 
by bottoms-up label-free mass spectrometry in Fig. 4. Ingenuity pathway analysis revealed significant (p < 0.05) 
dysregulation in a number of proteins involved in EMT, (red = upregulation, green = downregulation). (b)
PCR and Western blotting was carried out in order to validate the EMT dysregulation identified by mass 
spectrometry in part a. PCR data showed downregulation of E-cadherin and upregulation of Zeb1 & Zeb2 
mRNA expression in H1975GR vs H1975GP. Western blot analysis showed elevated vimentin expression.
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mostly including neurological developmental defects due to its known role in brain development34. In relation 
to cancer, AKT3 has been implicated in the development of glioblastoma multiforme35, malignant melanoma36 
and may contribute to a more aggressive clinical phenotype in estrogen receptor-negative breast cancers and 
androgen-insensitive prostate carcinomas37. Furthermore, AKT3 may contribute to cisplatin resistance in human 
uterine cancer cells38. Increased expression of AKT3 was associated with a decrease in expression of ERS2 in 
H1975GR cells, and a decrease in expression of ESR1 in H460GR cells. Correspondingly, in a study by Grabinski 
et al. (32), inactivation of AKT3 was shown to result in increased expression of ERα. AKT3 was also shown to 
regulate ERBB2 and ERBB3, which are both upregulated in H460GR cells. Recently, knockdown of AKT3 in 
conjunction with PIK3CA has been shown to suppress cell viability and proliferation and induce apoptosis of glio-
blastoma multiforme cells39, and AKT3 has been implicated in resistance to the AKT inhibitor, MK220640. With 
increasing interest in a role for AKT3 in cancer, there may be a future role for AKT3 targeted therapies, which we 
hypothesize may be useful in the setting of PI3K-mTOR inhibitor resistance.
Based on previous work in acquired resistance to PI3K inhibition9, the IGF-1 pathway was anticipated to play 
a role in acquired resistance to Apitolisib (GDC-0980) here. While there was some dysregulation of the pathway 
observed in H1975GR cells by mass spectrometry, there was nothing to suggest a categorical shift to IGF1 signal-
ling. Again in H460GR cells, there was some dysregulation of IGF related genes observed at the level of mRNA, 
but nothing to suggest a significant shift in signalling to this pathway. H460GR cells displayed a marked switch 
from EGFR expression to ERBB2, ERBB3 and ERBB4 expression which may imply a targetable bypass mechanism 
of resistance is underway in these cells. Based on the known level of cross talk between the PI3K and MAPK path-
ways and previously published synergistic interaction between PI3K and MEK inhibitors in NSCLC32, it was also 
anticipated that MAPK signalling may play a role in Apitolisib (GDC-0980) resistance. While some MAPK family 
proteins were differentially regulated in H1975 cells, as observed by mass spectrometry, there was no evidence of 
a categorical shift in signalling.
Growing data underpins the importance of EMT in lung cancer, with cells that take on a more mesenchymal 
phenotype becoming more motile, allowing for increased aggression and therefore tumour progression. A recent 
study found that EMT marker expression in the leading edge of NSCLC tumours correlates with advanced stage 
and poor differentiation41, with other recent studies highlighting the association between EMT and proliferation 
and invasion42, metastasis43 and poor prognosis44 in NSCLC. A growing body of evidence supports a role for EMT 
in resistance to targeted therapies in NSCLC and other cancers45, with the EMT phenotype seemingly allowing 
cells to overcome drug inhibition. Resistance to sorafenib, a tyrosine kinase inhibitor that targets proteins such 
as VEGF, PDGFR and the Raf family, has recently been shown to be mediated by EMT using xenografts from an 
A549 cell line model of resistance46. An A549 cell line model of resistance to gefitinib (an EGFR inhibitor) has also 
been recently published, again with EMT identified as a potential mechanism of resistance due to altered EMT 
marker expression47. Here, proteomics analysis revealed a dysregulation in pathways related to EMT in H1975GR 
cells. miR205-5p, was noted to be overexpressed in H1975GR cells, which has been shown to target genes that 
regulate EMT, and is associated with cancer progression48. Further investigations confirmed dysregulation of 
well-known EMT markers E-cadherin, vimentin, Zeb1 and Zeb 2 in this cell line, supporting this aggressive EMT 
phenotype in H1975GR cells. H1975GR cells were shown to overexpress miR-1260b and miR-19a-3p, which have 
been linked with lymph node metastasis in NSCLC and colorectal cancer respectively, supporting the aggressive 
phenotype of these cells49,50.
These data strengthen the evidence base for the roles of EMT, AKT3 and the ERBB family in targeted therapy 
resistance. These cell line models of resistance, along with the molecular characterisation datasets made available 
here, will provide a valuable resource to study targeted therapy resistance moving forward, particularly as the cell 
lines are resistant to both Apitolisib (GDC-0980) and Dactolisib (BEZ235).
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